placebo + molnupiravir

This is a combination of two components: a placebo and molnupiravir. Placebo refers to an inert substance with no pharmacological activity, commonly used as a control in clinical trials to assess the efficacy of active treatments[7][10]. Molnupiravir is an orally bioavailable small molecule antiviral prodrug that is metabolized into N4-hydroxycytidine, which incorporates into viral RNA and induces errors during replication, leading to inhibition of SARS-CoV-2 (the virus responsible for COVID-19) replication through viral error catastrophe[1][5][6]. Molnupiravir has been developed primarily for the treatment of mild-to-moderate COVID-19 in adults at risk for severe disease when other options are not available or appropriate[2][3][8]. The combination "placebo + molnupiravir" typically refers to arms in clinical trials where one group receives only a placebo and another receives active drug; however, if considered as a product, it would be an investigational combination used solely within controlled studies.

Other names

EIDD-2801 + placeboMK-4482 + placebo